NEWS & PRESS
Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of Antibodies and Payloads for Preparation of DAR1 ADC
STRASBOURG (France) – January 28, 2020 – Syndivia has acquired an exclusive license from SATT Conectus for DARx technology, which enables the generation of 1-to-1 conjugates (DAR1) using readily available protein substrates, such as therapeutic antibodies. The antibody-drug and antibody-oligonucleotide conjugates with a degree of conjugation of 1 (DAR1), produced through DARx, have demonstrated improved therapeutic indices owing to enhanced pharmacokinetics and pharmacodynamics (PK/PD) parameters.
Syndivia In-Licenses Novel Antibody Against Tumor-Specific Form of CD146 From SATT Sud-Est
Syndivia receives the exclusive sublicense specifically for immunoconjugates of the monoclonal antibody against the tumor-specific form of CD146 (CD146-ts mAb).
CD146-ts is a promising target and represents a first-in-class opportunity for the treatment of a number of solid cancers, including melanoma and pancreatic cancer.
STRASBOURG (France) and MARSEILLE (France) – January 16, 2020 – Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumor microenvironment and anatomical hallmarks, announced today that it has been granted an exclusive, worldwide sublicense by SATT Sud-Est to the immunoconjugates of the anti‑CD146-ts antibody (excluding diagnosis), which binds a tumor-specific form of CD146 found on a number of solid cancers. CD146-ts has a central role in the mechanism of tumorigenesis and has the potential to address a current unmet need in cancer therapy. The development of novel biologic entities (NBE) targeting CD146-ts will be undertaken by Syndivia in Strasbourg, France.
Commenting on this deal, Dr. Sasha KONIEV, Syndivia’s CEO, said “We are excited to have been granted the sole and exclusive sublicense to commercialize the immunoconjugates against this tumor-specific form of CD146. We are enthusiastic about the addition of this candidate to the Syndivia discovery pipeline and will leverage our expertise in bioconjugation to rapidly progress its preclinical development.”
“We are extremely pleased that Syndivia shares our excitement for the CD146-ts mAb project and look forward to the next stages of development with great enthusiasm,” said Dr. Marcel BLOT-CHABAUD, inventor of anti-CD146-ts antibody and leader of the “New Molecular Targets” team at C2VN, Aix-Marseille Université, INSERM, INRA, Marseille, France.
"We could not be any happier when transferring such a first-in-class opportunity for the treatment of solid cancers, with the sole aim of transforming the invention into an innovation – especially when the nature of the identified target makes it possible to identify a relevant lead for the most aggressive and refractory forms to current treatments,” concluded Laurent BALY, President of SATT Sud-Est.
Syndivia will undertake further development and commercialization of anti-CD146-ts immunoconjugates in exchange for undisclosed upfront, milestone and royalty payments to SATT Sud-Est.
About CD146-ts
CD146-ts represents a novel target in a number of the deadliest therapeutic indications in oncology, including melanoma and pancreatic cancer. Due to its important role in tumorigenesis and confirmed tumor-specific expression in patient-derived samples, anti-CD146-ts immunoconjugates have the potential to become new therapeutic modalities in a number of solid cancer indications.
About C2VN (Aix-Marseille Université, INSERM, INRA)
The Cardiovascular and Nutrition Research Centre (C2VN, UMR_S 1263, UMR 1260, Aix-Marseille Université, INSERM, INRA) shows expertise in all pathways and targets involved in pathologies with a vascular component, including cancer pathology, with the aim of identifying innovative biomarkers and biotherapies. To support its studies, the C2VN has developed many platforms, tools and experimental models related to the targeted pathologies. For more information, visit https://c2vn.univ-amu.fr.
About SATT Sud-Est | From dream to reality, from lab to market
A researcher and his/her team make an extraordinary discovery. But how can an idea be transformed into a solution, and how can an invention be turned into an innovation? This is the start of a race against time to find the partner company capable of upholding that ambition. Fortunately, SATT Sud-Est is there to help in this undertaking and make this great story come true. Transforming an invention into an innovation is a wonderful experience. And we’re fortunate, it is our job. Find out how SATT Sud-Est accelerates technology transfer by bringing together research and business players. From the patent to the operating license agreement, SATT Sud-Est stands out in France’s South and Corsica regions as an essential innovation player. Visit www.sattse.com and twitter @SATTse_
About Syndivia
Syndivia is a research-driven biotechnology company that is developing a pipeline of targeted therapies for solid cancers by leveraging a unique microenvironment and anatomical hallmarks for these tumors. Syndivia’s mission is to develop new therapies for patients with the most difficult cancer indications. For more information, visit https://www.syndivia.com.
Media Contact
Syndivia
Sasha KONIEV – CEO
Phone: +33 (0)3 67 10 42 20
email: enquiry@syndivia.com
https://www.prnewswire.com/news-releases/syndivia-in-licenses-novel-antibody-against-tumor-specific-form-of-cd146-from-satt-sud-est-300988302.html
Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform
STRASBOURG (France) – December 10, 2019 – Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on a specific targeting of the tumour microenvironment and anatomical hallmarks, announced a €1M investment from Cap Innov’Est, an inter-regionally based seed fund.
This funding will enable Syndivia to advance its pipeline of proprietary anticancer therapies, including its lead drug candidate (SDV1001), thus completing the preclinical “proof of concept” study of the targeting of the microenvironment of solid tumours.
Sasha Koniev, Syndivia’s CEO, said, “We are very pleased to see Cap Innov’Est joining the company’s founders. This funding will allow us to advance our drug platform for both small-molecule and biologics, which have the unique potential to address a wide range of solid cancer indications by harnessing the specific properties of the tumor microenvironment”.
Jean-François Rax, Investment Director at Cap Innov’Est said, “We are truly enthusiastic to be investing in such a promising company. We are convinced that Syndivia’s breakthrough approach in the hands of its experienced management team will be successful in delivering innovative and efficient treatments for cancer patients.”
About Syndivia
Syndivia is a company that is developing a platform for the targeted therapy of solid cancers by leveraging a unique microenvironment and anatomical hallmarks of these tumours. Syndivia’s mission is to develop new therapies for patients with the most difficult cancer indications. For more information, visit https://www.syndivia.com.
About Cap Innov’Est
Cap Innov’Est is a €45 M French regional seed fund (Grand Est, Bourgogne-Franche-Comté) dedicated to investing in young, innovative start-ups. It was launched in July 2014 and has invested in 25 start-ups to date. Cap Innov’Est is managed by Capital Grand Est along with its partner, Invest PME (Siparex group). Cap Innov’Est is supported by Fonds National d’Amorçage (National Seed Fund), Regions Grand Est and Bourgogne-Franche-Comté, SAFIDI, Caisse d’Epargne d’Alsace and Bourgogne/Franche-Comté, BNP Paribas and CIFC. For more information, visit http://www.capitalgrandest.eu
Media Contact:
Syndivia
Sasha Koniev – CEO
Phone: 00 33 3 67 10 42 20
Email: enquiry@syndivia.com
https://www.prnewswire.com/news-releases/syndivia-raises-1m-investment-to-advance-its-tumour-microenvironment-drug-delivery-platform-300972469.html
Syndivia is a laureate AstraZeneca's open innovation program - ReAliZe
STRASBOURG (France) – October 2, 2019 – Syndivia is nominated laureate of ReAliZe in the Scientific Innovation category. ReAliZe is an open innovation program of AstraZeneca supporting oncology start-ups and focusing on 4 main areas: data management, scientific innovation, patient care and artificial intelligence.
Syndivia and BFCL publish review of Antibody–Oligonucleotide Conjugates (AOC) as therapeutic, imaging, and detection agents
Syndivia and Biofunctional Chemistry Laboratory announce publication of a review titled “Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents” in Bioconjugate Chemistry. The review gives a comprehensive overview of the main applications of antibody-oligonucleotide conjugates (AOC) as well as major synthetic approaches used for their preparation. The review emphasized the importance of the development of novel methods for efficient and reliable generation of AOC, in order to advance their new applications.
